Personalized medicine is a rapidly advancing field of healthcare that emphasizes tailoring of treatments and interventions with all identifying. Breast cancer is the first area where the concept of personalized medicine has been used. Breast cancer is a disease that can spread is now assumed that many different. However, until recently. There is no way to verify drug that works best for the patient cancer each. At this time. Multiple test based on genetics and proteomics market. These tests, especially proteomic test can predict which medication will work for each person with the highest level of accuracy as new technologies emerge and mature oncologists can formulate specific treatments for people resulting in better performance and avoid waste of time and the effect of undoing. Can identify treatments effective will also make substantial cost savings.
Cancer is highly individualized attention in American Cancer Society has estimated that near 1.5 million people will receive analysis with cancer in the United States and die 550000, rather than as a result of the disease annually in 2009, National Institutes of Health estimated direct medical costs of 2008 (total health expenditures) was $ 93.2 million. With total costs (including loss of productivity due to illness and death) Thousands of $ 228.1 million to these cost growth is growth driven by increased monitoring and the population aged.
Because every tumor looks different. Drug treatment is goal is how to. Effective treatment based on selected drugs only target the tumor (s) of the patient. Unfortunately, there are usually significant side as costs can exceed $ 30000 per year for one patient. Need for multiple target is important. It is not enough to identify individuals who may or may not have cancer, but now the challenge is to develop individualized attention, therapy regimens to treat sick disease.
Anticancer drugs are approved by the FDA on the basis of the clinical results from a population of parents of cancer. The response rate of 20-30% may drug regimen WINS FDA approval. Unable to use the results of these populations in the individual control because the cancer has advanced individualized attention.
At this time. There is no standard procedure for selecting the appropriate chemotherapy treatment.
Number of prognostic and predictive tests commercialized by genomic classification of breast cancer has entered the market grow for diagnostics test by immunohistochemistry (IHC) and Fluorescent in situ Hybridization (fish) is currently under testing breast cancer diagnostic guidelines. In this context. These two techniques most often used to evaluate the status HER-2 or hormone receptor evaluation of test results allow clinicians to choose illness often benefit from a consistent treatment properly. This market is currently counting on immigrants by an FDA approved product offering a large established company.
More recently. A number of prognostic and predictive tests commercialized by classification of breast cancer has entered the market expand genomic for Genomic assays Diagnostics check the expression of specific genes that may indicate a recurrence of cancer or the capability to respond to treatment with these Assays will be used as a basis to predict recurrence of breast cancer in current and will be expanded to that of hormonal receptor status and HER-2 competition in this segment are based on the introduction of different assays use and combination of various genes.
A leader in the market today is Genomic Health genomic which Oncotype Dx assay and Agendia which Mammaprint assay test for gene expression analysis of these and current suitable to predict recurrence of breast cancer, even if the contract is genomics technology limitations, some of these Assays is generally only a subset of the parents of cancer and is far from being a standard show significant variability and because a homogenized tissue for this type of analysis. All feelings of pok and the heterogeneity tissue lost to convert gene assays used to prove to be difficult. A single gene can produce a variety of different protein to show the potential of certain cancer cells.
Another type of diagnostic test based proteomics or analyze protein as breast cancer proteomics study is important because protein is responsible for both the structure and functions of organisms all direct analysis of the protein makes better images of actual cancer cell to respond to a given treatment by Proteomic tumor tests are available from CCC Diagnostics, who markets DirectHit Panel for breast cancer (directhittest.com), DirectHit Panel for breast cancer assay is estimated based on immunofluorescence test technologies across other DirectHit can standard by standard references only for operators, operators, and lab to lab, DirectHit offered with reproducibility analysis quantity of biomarkers that 5 to see one area of interest and can be used with effectiveness of cytotoxic drugs approximately DirectHit dichotomizes decision maintained with high precision level, most recently the clinic DirectHit Panel for breast cancer more accurately predict output up for therapy results. Anti drug Trastuzumab and estrogen than IHC DirectHit also shows the great predictive for response to chemotherapy (88%), DirectHit also shows specificity for extreme predictions of drug resistance (100%)
No need to maintain a sufficient breast cancer, should be welcome news for physicians and their patients.
Tidak ada komentar:
Posting Komentar